AstraZeneca Pharma India Limited has received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India, to import and distribute Sodium Zirconium Cyclosilicate powder for oral suspension, marketed as Lokelma.
This new drug approval, granted in Form CT-20, allows AstraZeneca to introduce Lokelma in 5 g and 10 g formulations for the treatment of hyperkalaemia in adult patients.
Hyperkalaemia, a condition characterized by elevated potassium levels in the blood, can be life-threatening if left untreated. Lokelma offers an effective treatment option by helping to regulate potassium levels safely and efficiently. With this approval, AstraZeneca is set to bring this advanced treatment to patients in India, subject to further statutory clearances.
The introduction of Sodium Zirconium Cyclosilicate in the Indian market marks a significant step in addressing hyperkalaemia, a condition often associated with chronic kidney disease and heart failure.
erkalaemia will soon have access to an effective, globally recognized treatment option.